SEP 30·SEC EDGARLow
Altman Peter purchased $1K of BCDA
Altman Peter (President and CEO) purchased 1,000 shares of BioCardia, Inc. (BCDA) at $1.03 on 2026-09-29.
StockNASDAQ · US · USDHealthcare · Biotechnology
$BCDA
BioCardia, Inc.
Price · $BCDAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $BCDA in the last 7 days.
Insider · 30dAll trades →
- Buys
- $4K 3 txs
- Sells
- — 0 txs
Altman Peter3× · $4K
10b5-1 share of filings0%
Top stories · $BCDAMore →
SEP 24·SEC EDGAR
Altman Peter purchased $2K of BCDA
Altman Peter (President and CEO) purchased 1,900 shares of BioCardia, Inc. (BCDA) at $1.05 on 2026-09-23.
SEP 23·SEC EDGAR 8-K
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif. – September 23, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of ca
BCDA sentiment & insider activity
Recent BCDA coverage spans insider activity, corporate actions and earnings.
In the last 30 days, BCDA insiders filed 3 SEC Form 4 transactions — 3 purchases ($4K) and no sales. The most active reporter was Altman Peter, President and CEO, with 3 filings.
What's driving BCDA
The purchase is very small relative to market cap and likely has negligible price impact.
Minor insider purchase with limited market impact.
Regulatory timeline updates could move the stock as investors reassess near‑term clearance risk.
Regaining compliance may reduce delisting risk but does not guarantee future price stability.
Regaining compliance removes delisting risk, potentially stabilizing the stock.
AlphAI scores every news story that mentions BCDA with an AI model for sentiment and relevance, and aggregates insider trades from BioCardia, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BCDA
Score
Altman Peter purchased $1K of BCDA
Altman Peter (President and CEO) purchased 1,000 shares of BioCardia, Inc. (BCDA) at $1.03 on 2026-09-29.
1 min readAltman Peter purchased $2K of BCDA
Altman Peter (President and CEO) purchased 1,900 shares of BioCardia, Inc. (BCDA) at $1.05 on 2026-09-23.
1 min readBioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif. – September 23, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of ca
2 min readBioCardia Shares Fall 10% After Hours: Here's Why
BioCardia Inc. (BCDA) shares dropped 10.19% to $0.97 in after-hours trading. The company reported regaining compliance with Nasdaq's $1 minimum bid price requirement. BioCardia's market cap is $16.35M, with shares down 2.7% over the past year. The stock traded between $1.80 and $0.75 in the last 52 weeks.
1 min readBioCardia, Inc. received a letter from the Listing Qualifications Department of The NASDAQ Stock Market, LLC indicating that, for the last 30 consecutive…
BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. As previously disclosed, on August 19, 2026, BioCardia, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The NASDAQ Stock Market, LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days,
1 min readAltman Peter purchased $872 of BCDA
Altman Peter (President and CEO) purchased 800 shares of BioCardia, Inc. (BCDA) at $1.09 on 2026-09-03.
1 min read
BioCardia (BCDA) Q2 2026 Earnings Call Transcript
BioCardia (BCDA) reported Q2 2026 earnings with $4.1M in cash, a net loss of $1.6M, and raised $4.9M via ATM facility. The company reduced R&D spending and is progressing with regulatory submissions for CardiAMP in Japan and the U.S. Management anticipates market approval in Japan by Q4 2027 and FDA premarket approval support from ongoing trials. BioCardia is also exploring partnerships and streamlining trials to enhance enrollment.
3 min readAltman Peter purchased $5K of BCDA
Altman Peter (President and CEO) purchased 5,400 shares of BioCardia, Inc. (BCDA) at $0.93 on 2026-08-17.
2 min readAltman Peter purchased $2K of BCDA
Altman Peter (President and CEO) purchased 1,900 shares of BioCardia, Inc. (BCDA) at $0.92 on 2026-08-13.
1 min read
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan
BioCardia (BCDA) reported Q2 2026 regulatory updates for its CardiAMP cell therapy and Helix delivery catheter. According to management, Japan’s PMDA supported a Shonin premarket submission, with approval expected about 12 months after filing. The FDA said CardiAMP Heart Failure 2 could support premarket approval and outlined two Helix clearance pathways. Q2 2026 net cash used in operations was ~$1.7M; cash ended at ~$5.4M.
4 min read